How has been the historical performance of Natco Pharma?

Answer:The historical performance of Natco Pharma shows significant growth in net sales and profitability over the years, culminating in the fiscal year ending March 2025.

Breakdown:
Natco Pharma's net sales have steadily increased from 1,915.00 Cr in March 2020 to 4,429.50 Cr in March 2025, reflecting a strong upward trend. The total operating income followed a similar trajectory, rising from 1,915.00 Cr in March 2020 to 4,429.50 Cr in March 2025. The operating profit (PBDIT) also demonstrated substantial growth, reaching 2,550.50 Cr in March 2025, up from 690.00 Cr in March 2020. Profit before tax increased from 568.70 Cr in March 2020 to 2,291.40 Cr in March 2025, while profit after tax surged from 458.10 Cr to 1,883.40 Cr in the same period. The earnings per share (EPS) rose significantly from 25.32 in March 2020 to 105.33 in March 2025, indicating improved shareholder value. On the balance sheet, total assets grew from 4,587.80 Cr in March 2020 to 8,580.70 Cr in March 2025, with total liabilities increasing from 4,587.80 Cr to 8,580.70 Cr. Cash flow from operating activities improved from 417.00 Cr in March 2020 to 1,696.00 Cr in March 2025, showcasing enhanced operational efficiency. Overall, Natco Pharma's financial metrics reflect a robust growth trajectory and improved profitability over the years.